Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H21NO3 |
Molecular Weight | 239.3107 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@H](NC(C)C)[C@@H](O)C1=CC(O)=C(O)C=C1
InChI
InChIKey=HUYWAWARQUIQLE-MFKMUULPSA-N
InChI=1S/C13H21NO3/c1-4-10(14-8(2)3)13(17)9-5-6-11(15)12(16)7-9/h5-8,10,13-17H,4H2,1-3H3/t10-,13+/m1/s1
Isoetharine is a beta-2 adrenergic receptor agonist, which was developed by Max Bockmuhl, Gustav Erhart and Leonhard Stein at the Hochst laboratories of I.G. Farbenindustrie in 1934. By binding to beta-2 adrenergic receptors on bronchial cell membranes, isoetharine increases the level of cAMP and thus stimulates the relaxation of smooth-muscle cells, stabilizes mast cells and inhibits histamine release. Isoetharine was approved by FDA for the symptomatic relief of bronchiospasms in patients with chronic bronchitis or emphysema (aerosol and solution for inhalation), however, later on the drug was discontinued.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P07550|||Q53GA6|||Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) Sources: www.ncbi.nlm.nih.gov/pubmed/11283 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | BRONKOSOL Approved UseTo prevent and treat reversible bronchospasm from chronic bronchitis or emphysema. |
|||
Palliative | BRONKOSOL Approved UseTo prevent and treat reversible bronchospasm from chronic bronchitis or emphysema. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
162 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7120101/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOETHARINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
498 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7120101/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOETHARINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7120101/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOETHARINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 4 times / day multiple, oral Dose: 20 mg, 4 times / day Route: oral Route: multiple Dose: 20 mg, 4 times / day Sources: |
unhealthy, 29-72 years n = 39 Health Status: unhealthy Age Group: 29-72 years Sex: M+F Population Size: 39 Sources: |
Other AEs: Tremor, Tremor... |
5 mg 1 times / hour multiple, respiratory Dose: 5 mg, 1 times / hour Route: respiratory Route: multiple Dose: 5 mg, 1 times / hour Sources: |
unhealthy, 35 ± 3.31 years Health Status: unhealthy Age Group: 35 ± 3.31 years Sex: M+F Sources: |
Disc. AE: Nervousness... AEs leading to discontinuation/dose reduction: Nervousness (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Tremor | 1 patient | 20 mg 4 times / day multiple, oral Dose: 20 mg, 4 times / day Route: oral Route: multiple Dose: 20 mg, 4 times / day Sources: |
unhealthy, 29-72 years n = 39 Health Status: unhealthy Age Group: 29-72 years Sex: M+F Population Size: 39 Sources: |
Tremor | 2 patients | 20 mg 4 times / day multiple, oral Dose: 20 mg, 4 times / day Route: oral Route: multiple Dose: 20 mg, 4 times / day Sources: |
unhealthy, 29-72 years n = 39 Health Status: unhealthy Age Group: 29-72 years Sex: M+F Population Size: 39 Sources: |
Nervousness | 1 patient Disc. AE |
5 mg 1 times / hour multiple, respiratory Dose: 5 mg, 1 times / hour Route: respiratory Route: multiple Dose: 5 mg, 1 times / hour Sources: |
unhealthy, 35 ± 3.31 years Health Status: unhealthy Age Group: 35 ± 3.31 years Sex: M+F Sources: |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R03CC06
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
||
|
WHO-ATC |
R03AC07
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
||
|
WHO-VATC |
QR03AC07
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
||
|
WHO-VATC |
QR03CC06
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
||
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1491
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
Isoetharine
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
208-472-1
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
100000082809
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
7205
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
ISOETARINE
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
530-08-5
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
DTXSID9048560
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
1384
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
m6485
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1201213
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
D007528
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
YV0SN3276Q
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
DB00221
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
6023
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | RxNorm | ||
|
71466
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
79490-84-9
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
C65974
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY | |||
|
SUB08316MIG
Created by
admin on Fri Dec 15 16:31:32 GMT 2023 , Edited by admin on Fri Dec 15 16:31:32 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)